Matches in Wikidata for { <http://www.wikidata.org/entity/Q34172753> ?p ?o ?g. }
- Q34172753 description "2011 nî lūn-bûn" @default.
- Q34172753 description "2011 թուականի Մարտին հրատարակուած գիտական յօդուած" @default.
- Q34172753 description "2011 թվականի մարտին հրատարակված գիտական հոդված" @default.
- Q34172753 description "2011年の論文" @default.
- Q34172753 description "2011年論文" @default.
- Q34172753 description "2011年論文" @default.
- Q34172753 description "2011年論文" @default.
- Q34172753 description "2011年論文" @default.
- Q34172753 description "2011年論文" @default.
- Q34172753 description "2011年论文" @default.
- Q34172753 description "2011年论文" @default.
- Q34172753 description "2011年论文" @default.
- Q34172753 description "2011年论文" @default.
- Q34172753 description "2011年论文" @default.
- Q34172753 description "2011年论文" @default.
- Q34172753 description "2011년 논문" @default.
- Q34172753 description "article científic" @default.
- Q34172753 description "article scientific" @default.
- Q34172753 description "article scientifique (publié 2011)" @default.
- Q34172753 description "articol științific" @default.
- Q34172753 description "articolo scientifico" @default.
- Q34172753 description "artigo científico (publicado na 2011)" @default.
- Q34172753 description "artigo científico (publicado na 2011)" @default.
- Q34172753 description "artigo científico" @default.
- Q34172753 description "artikull shkencor" @default.
- Q34172753 description "artikulong pang-agham" @default.
- Q34172753 description "artykuł naukowy" @default.
- Q34172753 description "artículo científico publicado en 2011" @default.
- Q34172753 description "artículu científicu espublizáu en 2011" @default.
- Q34172753 description "bilimsel makale" @default.
- Q34172753 description "bài báo khoa học" @default.
- Q34172753 description "mokslinis straipsnis" @default.
- Q34172753 description "naučni članak" @default.
- Q34172753 description "scienca artikolo" @default.
- Q34172753 description "scientific article" @default.
- Q34172753 description "teaduslik artikkel" @default.
- Q34172753 description "tieteellinen artikkeli" @default.
- Q34172753 description "tudományos cikk" @default.
- Q34172753 description "vedecký článok" @default.
- Q34172753 description "vetenskaplig artikel" @default.
- Q34172753 description "videnskabelig artikel (udgivet 2011)" @default.
- Q34172753 description "vitenskapelig artikkel" @default.
- Q34172753 description "vitskapeleg artikkel" @default.
- Q34172753 description "vědecký článek" @default.
- Q34172753 description "wetenschappelijk artikel" @default.
- Q34172753 description "wissenschaftlicher Artikel" @default.
- Q34172753 description "επιστημονικό άρθρο" @default.
- Q34172753 description "мақолаи илмӣ" @default.
- Q34172753 description "мақолаи илмӣ" @default.
- Q34172753 description "наукова стаття, опублікована в березні 2011" @default.
- Q34172753 description "научна статия" @default.
- Q34172753 description "научная статья" @default.
- Q34172753 description "научни чланак" @default.
- Q34172753 description "научни чланак" @default.
- Q34172753 description "מאמר מדעי" @default.
- Q34172753 description "سائنسی مضمون" @default.
- Q34172753 description "مقالة علمية" @default.
- Q34172753 description "مقالهٔ علمی" @default.
- Q34172753 description "২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q34172753 description "บทความทางวิทยาศาสตร์" @default.
- Q34172753 description "სამეცნიერო სტატია" @default.
- Q34172753 name "Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study" @default.
- Q34172753 name "Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study" @default.
- Q34172753 name "Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study" @default.
- Q34172753 type Item @default.
- Q34172753 label "Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study" @default.
- Q34172753 label "Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study" @default.
- Q34172753 label "Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study" @default.
- Q34172753 prefLabel "Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study" @default.
- Q34172753 prefLabel "Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study" @default.
- Q34172753 prefLabel "Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study" @default.
- Q34172753 P1433 Q34172753-6B808930-82A9-4338-BC45-DE756C38F576 @default.
- Q34172753 P1476 Q34172753-B55224C2-B584-4429-9A91-6E579128D87B @default.
- Q34172753 P2093 Q34172753-229181D3-95C7-49DE-B52E-A31664C20FF9 @default.
- Q34172753 P2093 Q34172753-4399E5C1-C199-4840-B90E-8152E7D3D37E @default.
- Q34172753 P2093 Q34172753-493C0EE5-D22B-40DF-B00F-3E5AAC074EEB @default.
- Q34172753 P2093 Q34172753-4B9AD65A-D145-48B8-8542-31185F448D46 @default.
- Q34172753 P2093 Q34172753-88C4B0E4-7291-4931-BC08-658D331F6945 @default.
- Q34172753 P2093 Q34172753-8C1C959D-7AC6-4ED4-AC45-76B5AA65C275 @default.
- Q34172753 P2093 Q34172753-8F66D1EC-99F2-4B00-BD4F-586871B7047F @default.
- Q34172753 P2093 Q34172753-9DE447C2-A7AF-4159-AF88-85F778346C03 @default.
- Q34172753 P2093 Q34172753-A47C6162-7F53-4726-9BAB-150E7C3052FF @default.
- Q34172753 P2093 Q34172753-BB24D33C-DB23-450C-B4D0-3023D918ADB5 @default.
- Q34172753 P2093 Q34172753-C8B20D82-0FAC-47F2-9FDE-364F0CA87CEC @default.
- Q34172753 P2093 Q34172753-CC5F8F32-F643-4E83-B754-44F2C470B701 @default.
- Q34172753 P2093 Q34172753-D6E22CA5-AD28-4384-97F2-81DC0C613AA4 @default.
- Q34172753 P2093 Q34172753-DFF5343F-510A-40AD-AE8E-34E4A4039364 @default.
- Q34172753 P2093 Q34172753-E3EF8B70-FF2A-43FC-932C-1ABBFD5F2DC0 @default.
- Q34172753 P2093 Q34172753-EB52E494-58F4-452B-85F9-E8DE9D38B81F @default.
- Q34172753 P2093 Q34172753-F0A383F0-4779-4CEE-BFDC-9C1EB7435F0A @default.
- Q34172753 P2093 Q34172753-F5D1EF96-59CA-4F8D-8C1A-0ECA125365B9 @default.
- Q34172753 P2093 Q34172753-F7B3CED3-E2DF-4FC1-A6FE-4B2D4BC1EEEB @default.
- Q34172753 P2093 Q34172753-F83FFD9A-5F65-42B4-B1A6-0F3409E17A22 @default.
- Q34172753 P2860 Q34172753-18785DCA-6ECE-479D-B9BC-530459FB0C4C @default.
- Q34172753 P2860 Q34172753-3A46B7E1-B035-483A-96A7-D6D4C707B15A @default.
- Q34172753 P2860 Q34172753-3D029F97-5F7D-4D28-9B6B-BEF67E6A12EB @default.
- Q34172753 P2860 Q34172753-4565A59E-4B52-4AC3-82CD-EDC273922B03 @default.
- Q34172753 P2860 Q34172753-625BCC4E-7741-4989-802B-7517639DFA59 @default.
- Q34172753 P2860 Q34172753-62D037D8-A661-43D1-B177-3C917F72C33E @default.
- Q34172753 P2860 Q34172753-65E1C74D-7798-425F-838B-51A24FA25EE8 @default.